Andelyn Biosciences Establishes Commercial-Scale Gene Therapy Manufacturing Facility in Ohio

Company Name: Andelyn Biosciences
Location: Columbus
Industry Sector: Healthcare
Company Profile: Andelyn Biosciences is a clinical manufacturer of materials for Phase 1, 2, and 3 gene therapy clinical studies for global biotechnology and pharmaceutical industries.
Company Website: www.andelynbio.com

Project Summary:

• Type of Project: New location
• Jobs Committed: 170

Company Need:

Andelyn Biosciences represents an important evolution of Nationwide Children’s current success in clinical manufacturing and gene therapy. The company sought to create a new state-of-the-art contract development and manufacturing organization (CDMO) facility. The facility will expand Andelyn Biosciences’ capabilities to include commercial-scale production.

Testimonial:

“This is an exciting time for Andelyn Biosciences as we are one step closer to offering a wider portfolio of capabilities and services that will ultimately be game changing for our clients. I want to thank all of our local partners for their support. Together, we are working to serve many patients around the world who need life-saving therapies.” – Mayo Pujols, CEO, Andelyn Biosciences

Why Ohio?

Andelyn Biosciences will establish the facility in Columbus, home of Nationwide Children’s Hospital, within The Ohio State University’s Innovation District. The 185,000 square foot facility will add a critical element to central Ohio’s cell and gene therapy ecosystem as world-class researchers, biotechnology facilities and a growing investor base have created a hub of gene therapy excellence.

Anchored by the Research Institute at Nationwide Children’s Hospital and The Ohio State University, both in Columbus, the state of Ohio has become fertile ground for the rapidly evolving gene therapy industry. World-class researchers, high-tech facilities and a growing investor base fuel an ecosystem that is creating startups and attracting both entrepreneurs and international investment to highly regarded healthcare hubs.

The project is being assisted with a $5 million JobsOhio Research and Development Center Grant. Opening in 2022, this will be central Ohio’s first commercial-scale Good Manufacturing Practices (cGMP) production facility devoted to gene therapies.

Read the full release here.

Collaborators:

JobsOhio, One Columbus, The Columbus Partnership, the city of Columbus, Columbus City Schools, and Rev1 Ventures